Strategic Acquisition Coldstream Laboratories was acquired by Piramal Enterprises in 2015 for about $30 million, indicating strong strategic value recognized by a major pharma group. This history suggests continuity in contract manufacturing for sterile injectables and potential access to Piramal’s broader customer base and global distribution network.

Aseptic Excellence The company specializes in aseptic and non-aseptic drug product manufacturing with a mobile isolator technology and an FDA-approved sterile facility, presenting opportunities for outsourcing, fast scale-up, and containment of potent or radiolabeled products for pharma clients seeking high-containment capabilities.

Niche Capabilities Capabilities include parenteral formulation, liquid and lyophilized dosage forms, in-house analytical chemistry, pre-formulation, and an onsite microbiology lab for method validation and micro testing, enabling end-to-end development and manufacturing partnerships with speed and flexibility.

Mid-Mized Scale With 11-50 employees and revenue in the mid-range, Coldstream offers a boutique CDMO profile suitable for mid-size biotech and specialty pharma companies seeking personalized service, potential for stepped collaborations, and easier alignment compared to larger CROs/CDMOs.

Growth Levers Sourcing opportunities exist in sterile injectable development and fill-finish, radiolabeled and potent compound containment, and potential cross-sell with Piramal’s global platforms. Prospects include expanding into multinational customer bases and leveraging Coldstream’s speed and flexibility for urgent or high-containment programs.